Show notes
Welcome to the latest Midlife Minute.
Today, I’m answering listeners’ questions about cardiovascular risk, focusing on Lp(a), LDL, statins, and the changes women experience after menopause.
Stay tuned for more!
IN THIS EPISODE, YOU WILL LEARN:
Why women should have their Lp(a) checked both before and after menopause
How Lp(a) works as a risk enhancer, and how cardiovascular risk becomes more significant when elevated Lp(a) occurs alongside high LDL
Why family history is particularly helpful for women with a 10-year calculated cardiovascular risk that looks reassuringly low
I review the current guidelines for primary prevention
Why, even though research has shown reductions in major cardiac events with GLP-1s, GLP-1s do not replace statins for lowering LDL
What a CAC score can reveal about coronary artery calcification, and what it cannot detect
How AI-assisted CT angiography (such as Clearly) can map, quantify, and characterize plaque throughout the coronary branches
Connect with Cynthia Thurlow
Follow on X, Instagram & LinkedIn
Check out Cynthia’s website.
Submit your questions to [email protected]
Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.
Purchase Cynthia’s book, The Menopause Gut.
Cynthia’s Intermittent Fasting Transformation Book
The Midlife Pause Supplement Line
References:
1. Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML.Recent
2. Sex Differences of Lipoprotein(a) Levels and Associated Risk of Morbidity and Mortality by Age: The Copenhagen General Population Study. Atherosclerosis. 2022. Simony SB, Mortensen MB, Langsted A, et al.
3. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022. Stone NJ, Smith SC, Orringer CE, et al.Review
4. Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a). JAMA Cardiology. 2026. Nordestgaard AT, Chasman DI, Moorthy V, et al.RecentObservational
5. Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg
6. Clinical Practice Guideline on Lipid Management for Cardiovascular Disease Risk Reduction.
Department of Veterans Affairs (2026). 2026. Paul Heidenreich, Lance Spacek, Neil Gregor, et al. Guideline
7. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk.
Journal of the American College of Cardiology. 2020. Mehta A, Virani SS, Ayers CR, et al.Observational
8. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2010. Greenland P, Alpert JS, Beller GA, et al.Guideline
9. Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women.
The Journal of the American Medical Association. 2016. Kavousi M, Desai CS, Ayers C, et al.SR
10. Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as “Low Risk” Based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA). Archives of Internal Medicine. 2007. Lakoski SG, Greenland P, Wong ND, et al.Observational
11. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019. Arnett DK, Blumenthal RS, Albert MA, et al.Guideline
12. HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 Words. Mayo Clinic Proceedings. 2020. Orringer CE, Maki KC.Review
13. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.
Journal of the American College of Cardiology. 2020. Cho L, Davis M, Elgendy I, et al.Review
14. Health Maintenance in Postmenopausal Women.
American Family Physician. 2025. Plesa M, Wong A, Katsaggelos E.Guideline
15. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
Diabetes Care. 2024. Lingvay I, Deanfield J, Kahn SE, et al.RCT
16. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The New England Journal of Medicine. 2023. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.RCT
17. Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial. Nature Medicine. 2024. Ryan DH, Lingvay I, Deanfield J, et al.RCT
18. Interventions for the Prevention and Management of Cardiometabolic Multiple Long-Term Conditions. Lancet. 2026. Valabhji J, Hope D, Sayed NE, et al.RecentReview
19. Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials.
Clinical Cardiology. 2024. Hosseinpour A, Sood A, Kamalpour J, et al.SR
20. FDA Orange Book. FDA Orange Book. 2026.
21. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.
Diabetes Care. 2026. American Diabetes Association Professional Practice Committee for Diabetes*.RecentGuideline
22. Premature Coronary Artery Disease in Women: Sex-Specific Risk Factors, Pathogenetic Mechanisms and Clinical Implications. Annals of Medicine. 2026. Li F, Hong D, Yang M, et al.RecentReview
23. Cardiovascular Disease Risk Factors in Women: The Impact of Race and Ethnicity: A Scientific Statement From the American Heart Association. Circulation. 2023. Mehta LS, Velarde GP, Lewey J, et al.Guideline
24. Preventing CVD in Women: Common Questions and Answers.
American Family Physician. 2023. Westfall E, Viere AB, Genewick JE.Review
25. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline